Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rita Cristina Myriam Intravaia has a total of 118 co-authors. Here are the top co-authors by number of shared publications:

  • Cristina Giannattasio

    Cardiology IV, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy; School of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy

    9 shared publications
  • Alessandro Maloberti

    Cardiology Department De Gasperis Cardio Center, Niguarda Hospital, 20162 Milan, Italy

    8 shared publications
  • Chiara Tognola

    Cardiology IV, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy

    6 shared publications
  • Giuseppina Novo

    Division of Cardiology, University Hospital “Paolo Giaccone”, Palermo, Italy

    4 shared publications
  • Benedetta De Chiara

    Cardiology 4, Cardio Center, ASST GOM Niguarda, Niguarda Hospital, Milan, Italy

    3 shared publications
  • Fabrizio Oliva

    Cardiology I, "A.De Gasperis" Department, ASST GOM Niguarda, Milan, Italy; Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO), Florence, Italy

    3 shared publications

Latest Publications

  • Open Access

    Beyond Coronary Stenosis: A Mechanism-Based Approach to Ischemic Heart Disease in Women

    by Chiara Tognola, Rita Cristina Myriam Intravaia, Giulia Colombo, Alberto Preda, Marisa Varrenti, Alessandro Maloberti, Patrizio Mazzone, Cristina Giannattasio, Fabrizio Guarracini

    Despite major advances in cardiovascular medicine, ischemic heart disease (IHD) in women remains underrecognized and undertreated. A substantial proportion of symptomatic women have no flow-limiting epicardial stenosis, and ischemia may arise from coronary microvascular dysfunction, vasospasm, diffuse atherosclerosis, plaque-related mechanisms, spontaneous coronary artery dissection (SCAD), or combinations of these processes. Female-specific biological factors—including hormonal transitions, vascular aging, inflammation, metabolic changes, and reproductive cardiovascular risk enhancers—modify the coronary substrate across the life course. This review integrates these determinants with contemporary coronary phenotyping and proposes a clinically oriented, mechanism-based framework for IHD in women. Multimodality imaging, invasive coronary functional testing, and intracoronary imaging are considered complementary tools for identifying predominant and coexisting mechanisms. Management should combine guideline-directed cardiovascular prevention with mechanism-targeted antianginal therapy and women-specific considerations, including reproductive planning, pregnancy counseling, medication safety, and psychosocial care. This framework is intended as a practical synthesis rather than a validated classification system and aims to support more precise diagnosis and individualized treatment of women with ischemic symptoms.

  • Open Access

    The role of inflammation in acute coronary syndrome: A systematic review on biochemical inflammatory assessment and anti-inflammatory therapies

    by Rita Cristina Myriam Intravaia, Chiara Tognola, Alessandro Maloberti, Filippo Brucato, Elisa Campione, Cristina Giannattasio, Marco Zuin, Marco Mojoli, Maurizio Giuseppe Abrignani, Fabrizio Oliva, et al.


  • Open Access

    Prevalence of hypertriglyceridemia and its association with extreme cardiovascular risk in patients with acute and chronic coronary syndrome enrolled in a cardiac rehabilitation program

    by Chiara Tognola, Davide Bernasconi, Rita Cristina Myriam Intravaia, Giulia Brioschi, Giorgio Toscani, Michela Algeri, Atea Shkodra, Elvira Inglese, Luciana Sciumè, Romano Danesi, et al.


  • Inquinamento acustico e malattie cardiovascolari

    by Maurizio Giuseppe Abrignani, Stefania Angela Di Fusco, Giulia Bugani, Rita Cristina Myriam Intravaia, Vincenzo Abrignani, Furio Colivicchi

    Diversi studi epidemiologici hanno rilevato che il rumore, in particolare quello connesso ai trasporti, può aumentare il rischio di morbilità e mortalità cardiovascolare, con evidenze più consistenti per la cardiopatia ischemica. Secondo l’Organizzazione Mondiale della Sanità, ogni anno nell’Europa occidentale si perdono oltre 1.6 milioni di anni di vita in buona salute a causa del rumore legato al traffico. Il rumore, specie notturno, provoca frammentazione e accorciamento del sonno, aumento dei livelli di ormoni dello stress e stress ossidativo, con effetti dannosi sul sistema cardio-cerebrovascolare. Questi fattori possono favorire la comparsa di disfunzione vascolare, infiammazione e ipertensione arteriosa, aumentando così il rischio di malattie cardiovascolari. In questa rassegna vengono affrontati gli effetti indiretti del rumore sulla salute cardiovascolare. In particolare, è fornita una panoramica aggiornata delle attuali ricerche epidemiologiche sugli effetti del rumore sui fattori di rischio e sulle malattie cardiovascolari, discutendo le ipotesi fisiopatologiche proposte dai più recenti studi clinici e sperimentali, volte a fornire una spiegazione attendibile di tale rapporto. Infine, vengono descritte le strategie attuali e future di mitigazione del rumore.


  • Carotid–femoral pulse wave velocity progression in hypertensive patients is associated with subsequent cardiovascular outcomes

    by Alessandro Maloberti, Paola Rebora, Giuseppe Occhino, Anita Andreano, Rita Cristina Myriam Intravaia, Chiara Tognola, Giorgio Toscani, Gabriele Peraro, Martina Morelli, Magda Rognoni, et al.

    Objective: Pulse wave velocity (PWV) is associated with cardiovascular events and mortality. However, little is known on the relationship of its progression (ΔPWV) over time with cardiovascular outcomes. The aim of our study was to evaluate the relationship between ΔPWV and all-cause mortality and cardiovascular events in hypertensive patients. Methods: We enrolled 402 consecutive hypertensive outpatients. At baseline, anamnestic, clinical, blood pressure (BP), laboratory data and PWV were assessed. PWV examination was repeated after 3.8 (I–III quartiles 3.5–4.2) years. Patients were subsequently followed for a median time of 10.1 (I–III quartiles 9.5–10.5) years recording all-cause mortality and cardiovascular events. Results: At baseline, mean age was 53.2 ± 13.0 years, SBP and DBP were 141.8 ± 17.5 and 86.8 ± 10.5 mmHg and PWV was 8.5 ± 1.9 m/s. Despite an improvement in BP control (−9.2 ± 19.5 and −8.0 ± 12.3 for SBP and DBP, respectively), at follow-up, the population showed a PWV increase (ΔPWV +0.6 ± 1.9 m/s). Progressors (ΔPWV ≥0.5 m/s, 204 patients, 50.7%) had a significantly lower survival probability and higher cumulative incidence of composite events, while no differences were seen for cardiovascular events (unadjusted analysis). At Cox multivariable analysis, neither ΔPWV at least 0.5 m/s (progressors) nor ΔPWV (as a spline function) were associated with cardiovascular events and with all-cause mortality. However, the association with survival probability and cumulative incidence of cardiovascular events, as a composite outcome, was significant (hazard ratio = 2.33, 95% CI 1.34–4.05, P = 0.003). Conclusion: Our study shows that PWV progression at least 0.5 m/s is frequent in hypertensive patients and is associated with a significantly higher risk of developing cardiovascular events or dying (composite outcome).


  • Open Access

    Secondary prevention and extreme cardiovascular risk evaluation (SEVERE-0): Prevalence of extreme cardiovascular risk in cardiological rehabilitation patients and its impact on functional improvement

    by Chiara Tognola, Rita Cristina Myriam Intravaia, Eleonora Senini, Stefano Pezzoli, Alfonso Riccio, Elena Gualini, Saverio Fabbri, Valentina Bellantonio, Francesco Politi, Marta Campana, et al.


  • Open Access

    Hyperuricemia in Cardiac Rehabilitation Patients: Prevalence and Association with Functional Improvement and Left Ventricular Ejection Fraction

    by Matteo Fortuna, Chiara Tognola, Michela Algeri, Atea Shkodra, Rita Cristina Myriam Intravaia, Stefano Pezzoli, Ilaria Garofani, Martina Morelli, Elena Gualini, Saverio Fabbri, et al.

    Introduction The role of uric acid (UA) and Hyper Uricemia (HU) in cardiac rehabilitation (CR) patients have been very little studied. Aim To evaluate the prevalence of HU and if it is associated to the functional improvement obtained or the left ventricular Ejection Fraction (EF) in CR patients after Acute or Chronic Coronary Syndrome (ACS and CCS respectively). Methods We enrol 411 patients (62.4 ± 10.2 years; males 79.8%) enrolled in the CR program at Niguarda Hospital (Milan) from January 2012 to May 2023. HU was defined both as the classic cut-off (> 6 for females, > 7 mg/dL for males) and with the newly identified one by the URRAH study (> 5.1 for females, > 5.6 mg/dL for males). All patients performed a 6MWT and an echocardiography at the beginning and at the end of CR program. Results Mean UA values were within the normal range (5.6 ± 1.4 mg/dL) with 19.5% (classic cut-off) HU patients with an increase to 47.4% with the newer one. Linear regression analysis showed no role for UA in determining functional improvement, while UA and hyperuricemia (classic cut-off) were associated to admission and discharge EF. The same was not with the URRAH cut-off. Conclusions HU is as frequent in CR patients as in those with ACS and CCS. UA didn’t correlate with functional recovery while it is associated with admission and discharge EF as also is for HU (classic cut-off). Whit the URRAH cut-off HU prevalence increases significantly, however, it doesn’t show any significant association with EF.


  • Open Access

    Cardiovascular Structural and Functional Parameters in Idiopathic Pulmonary Fibrosis at Disease Diagnosis

    by Paola Faverio, Alessandro Maloberti, Paola Rebora, Rita Cristina Myriam Intravaia, Chiara Tognola, Giorgio Toscani, Anna Amato, Valerio Leoni, Giovanni Franco, Federica Vitarelli, et al.

    Introduction Prevalence of cardiac and vascular fibrosis in patients with Idiopathic Pulmonary Fibrosis (IPF) has not been extensively evaluated. Aim In this study, we aimed to evaluate the heart and vessels functional and structural properties in patients with IPF compared to healthy controls. An exploratory analysis regarding disease severity in IPF patients has been done. Methods We enrolled 50 patients with IPF (at disease diagnosis before antifibrotic therapy initiation) and 50 controls matched for age and gender. Heart was evaluated through echocardiography and plasmatic NT-pro-brain natriuretic peptide that, together with patients’ symptoms, allow to define the presence of Heart Failure (HF) and diastolic dysfunction. Vessels were evaluated through Flow Mediated Dilation (FMD – endothelial function) and Pulse Wave Velocity (PWV—arterial stiffness) Results Patients with IPF had a prevalence of diastolic disfunction of 83.8%, HF of 37.8% and vascular fibrosis of 76.6%. No statistically significant difference was observed in comparison to the control group who showed prevalence of diastolic disfunction, HF and vascular fibrosis of 67.3%, 24.5% and 84.8%, respectively. Disease severity seems not to affect PWV, FMD, diastolic dysfunction and HF. Conclusions Patients with IPF early in the disease course do not present a significant CV fibrotic involvement when compared with age- and sex-matched controls. Bigger and adequately powered studies are needed to confirm our preliminary data and longitudinal studies are required in order to understand the time of appearance and progression rate of heart and vascular involvement in IPF subjects.


  • Open Access

    Secondary Prevention and Extreme Cardiovascular Risk Evaluation (SEVERE-1), Focus on Prevalence and Associated Risk Factors: The Study Protocol

    by Alessandro Maloberti, Rita Cristina Myriam Intravaia, Costantino Mancusi, Arturo Cesaro, Enrica Golia, Fucile Ilaria, Silvio Coletta, Piera Merlini, Benedetta De Chiara, Davide Bernasconi, et al.

    Introduction Despite significant improvement in secondary CardioVascular (CV) preventive strategies, some acute and chronic coronary syndrome (ACS and CCS) patients will suffer recurrent events (also called “extreme CV risk”). Recently new biochemical markers, such as uric acid (UA), lipoprotein A [Lp(a)] and several markers of inflammation, have been described to be associated with CV events recurrence. The SEcondary preVention and Extreme cardiovascular Risk Evaluation (SEVERE-1) study will accurately characterize extreme CV risk patients enrolled in cardiac rehabilitation (CR) programs. Aim. Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors. Aim Our aims will be to describe the prevalence of extreme CV risk and its association with newly described biochemical CV risk factors. Methods We will prospectively enrol 730 ACS/CCS patients at the beginning of a CR program. Extreme CV risk will be retrospectively defined as the presence of a previous (within 2 years) CV events in the patients’ clinical history. UA, Lp(a) and inflammatory markers (interleukin-6 and -18, tumor necrosis factor alpha, C-reactive protein, calprotectin and osteoprotegerin) will be assessed in ACS/CCS patients with extreme CV risk and compared with those without extreme CV risk but also with two control groups: 1180 hypertensives and 765 healthy subjects. The association between these biomarkers and extreme CV risk will be assessed with a multivariable model and two scoring systems will be created for an accurate identification of extreme CV risk patients. The first one will use only clinical variables while the second one will introduce the biochemical markers. Finally, by exome sequencing we will both evaluate polygenic risk score ability to predict recurrent events and perform mendellian randomization analysis on CV biomarkers. Conclusions Our study proposal was granted by the European Union PNRR M6/C2 call. With this study we will give definitive data on extreme CV risk prevalence rising attention on this condition and leading cardiologist to do a better diagnosis and to carry out a more intensive treatment optimization that will finally leads to a reduction of future ACS recurrence. This will be even more important for cardiologists working in CR that is a very important place for CV risk definition and therapies refinement.


  • Chemotherapy-related cardiac dysfunction: the usefulness of myocardial work indices

    by Daniela Di Lisi, Girolamo Manno, Cristina Madaudo, Clarissa Filorizzo, Rita Cristina Myriam Intravaia, Alfredo Ruggero Galassi, Lorena Incorvaia, Antonio Russo, Giuseppina Novo

    Aims: The role of left ventricular global longitudinal strain (GLS) in the diagnosis of subclinical cardiac damage induced by anticancer drugs is now consolidated. Considering some strain disadvantages such as the dependence on the haemodynamic loading conditions, the aim of our study was to investigate the usefulness of non-invasive myocardial work indices (MWI) derived from pressure–strain analysis, in the early diagnosis of cardiotoxicity. Methods and results: We enrolled 61 consecutive patients with breast cancer undergoing adjuvant treatment with anthracycline-containing chemotherapy followed by taxane + trastuzumab. Patients underwent a cardiological evaluation with 2D echocardiography including measurement of the left ventricular ejection fraction (LVEF) and other conventional parameters of systolic and diastolic function, GLS and MWI at baseline (T0), 3 months (T1) and 6 months (T2) after starting chemotherapy. At T1 and T2, we did not find a significant reduction in LVEF but we found a significant reduction in GLS and MWI (p value < 0.05). In addition, at T2, 31% of patients developed subclinical cardiac dysfunction defined as a relative decrease ≥ 12% of GLS from baseline. Global work index (GWI), global constructive work (GCW) and global work efficiency (GWE) decreased significantly in both patients with subclinical dysfunction and in those without subclinical dysfunction (p value < 0.05). Patients with subclinical dysfunction at T2 showed lower values of GCW at T0. Conclusion: MWI changed significantly during chemotherapy and appeared to alter precociously compared to GLS. Therefore, a multiparametric approach including left ventricular GLS and MWI measurements should be used in the evaluation of patients undergoing cardiotoxic antineoplastic treatment. Graphical Abstract